Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
Author:
Amstutz Alain123, Chammartin Frédérique1, Audigé Annette4, Eichenberger Anna L5, Braun Dominique L46, Amico Patrizia7, Stoeckle Marcel P8, Hasse Barbara6, Papadimitriou-Olivgeris Matthaios9, Manuel Oriol9ORCID, Bongard Cédric10, Schuurmans Macé M11, Hage René11, Damm Dominik11, Tamm Michael12, Mueller Nicolas J6, Rauch Andri5ORCID, Günthard Huldrych F46ORCID, Koller Michael T713, Schönenberger Christof M1, Griessbach Alexandra1, Labhardt Niklaus D1, Kouyos Roger D46, Trkola Alexandra4ORCID, Kusejko Katharina6ORCID, Bucher Heiner C1, Abela Irene A46, Briel Matthias114ORCID, Speich Benjamin1ORCID, , Abela I, Aebi-Popp K, Anagnostopoulos A, Battegay M, Bernasconi E, Braun D L, Bucher H C, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux C A, Günthard H F, Hachfeld A, Haerry D, Hasse B, Hirsch H H, Hoffmann M, Hösli I, Huber M, Jackson-Perry D, Kahlert C R, Kaiser L, Keiser O, Klimkait T, Kouyos R D, Kovari H, Kusejko K, Labhardt N, Leuzinger K, Martinez de Tejada B, Marzolini C, Metzner K J, Müller N, Nemeth J, Nicca D, Notter J, Paioni P, Pantaleo G, Perreau M, Rauch A, Salazar-Vizcaya L, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Wandeler G, Weisser M, Yerly S, , Amico Patrizia, Aubert John-David, Banz Vanessa, Beckmann Sonja, Beldi Guido, Berger Christoph, Berishvili Ekaterine, Berzigotti Annalisa, Binet Isabelle, Bochud Pierre-Yves, Branca Sanda, Bucher Heiner C, Catana Emmanuelle, Cairoli Anne, Chalandon Yves, De Geest Sabina, De Rougemont Olivier, De Seigneux Sophie, Dickenmann Michael, Dreifuss Joëlle Lynn, Duchosal Michel, Fehr Thomas, Ferrari-Lacraz Sylvie, Garzoni Christian, Golshayan Déla, Goossens Nicolas, Haidar Fadi, Halter Jörg, Heim Dominik, Hess Christoph, Hillinger Sven, Hirsch Hans H, Hirt Patricia, Hoessly Linard, Hofbauer Günther, Huynh-Do Uyen, Immer Franz, Koller Michael, Laesser Bettina, Lamoth Frédéric, Lehmann Roger, Leichtle Alexander, Manuel Oriol, Marti Hans-Peter, Martinelli Michele, McLin Valérie, Mellac Katell, Merçay Aurélia, Mettler Karin, Mueller Nicolas J, Müller-Arndt Ulrike, Müllhaupt Beat, Nägeli Mirjam, Oldani Graziano, Pascual Manuel, Passweg Jakob, Pazeller Rosemarie, Posfay-Barbe Klara, Rick Juliane, Rosselet Anne, Rossi Simona, Rothlin Silvia, Ruschitzka Frank, Schachtner Thomas, Schaub Stefan, Scherrer Alexandra, Schnyder Aurelia, Schuurmans Macé, Schwab Simon, Sengstag Thierry, Simonetta Federico, Stampf Susanne, Steiger Jürg, Stirnimann Guido, Stürzinger Ueli, Van Delden Christian, Venetz Jean-Pierre, Villard Jean, Vionnet Julien, Wick Madeleine, Wilhelm Markus, Yerly Patrick
Affiliation:
1. Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel , Basel , Switzerland 2. Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital, University of Oslo , Oslo , Norway 3. Population Health Sciences, Bristol Medical School, University of Bristol , Bristol , United Kingdom 4. Institute of Medical Virology, University of Zurich , Zurich , Switzerland 5. Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland 6. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich , Zurich , Switzerland 7. Clinic for Transplantation Immunology and Nephrology, University Hospital Basel , Basel , Switzerland 8. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel , Basel , Switzerland 9. Infectious Diseases Service and Transplantation Center, Lausanne University Hospital , Lausanne , Switzerland 10. Division of Pulmonology, Department of Medicine, University Hospital of Lausanne , Lausanne , Switzerland 11. Division of Pulmonology, University Hospital Zurich , Zurich , Switzerland 12. Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel , Basel , Switzerland 13. Swiss Transplant Cohort Study, University Hospital Basel , Basel , Switzerland 14. Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada
Abstract
Abstract
Background
Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination.
Methods
Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months postvaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/mL (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics.
Results
In SHCS participants, baseline anti-spike antibody concentrations ≥1642 units/mL were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642 units/mL, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a 5-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events.
Conclusions
Bivalent mRNA vaccination elicited a robust humoral response in individuals with human immunodeficiency virus (HIV) or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare.
Clinical Trials Registration . NCT04805125.
Funder
Moderna Swiss National Science Foundation Roche University of Basel Janggen Pöhn Foundation
Publisher
Oxford University Press (OUP)
|
|